VECT-HORUS starts the regulatory preclinical development of VH-N439, positioned as a first-in-class neuroprotective agent in brain ischemia
Neurotensin is a neuropeptide with global hypothermic potential when administered directly into the brain, but unable to cross the blood-brain barrier (BBB) when administrated alone systemically. The Company has developed VH-N439, a new chemical entity based on the conjugation of one of its peptide-vectors to an analogue of neurotensin.
Using in vivo models, the company has already shown improved potent hypothermia effects of VH-N439 compared to those obtained with free neurotensin. Interestingly, when it is administered by intravenous perfusion, VH-N439 induced a hypothermic effect that was maintained for several hours. This long-duration effect is of great interest since a long-term hypothermia is essential to treat patients following cardiac arrest or neonatal hypoxia/ischemia. Effects on neuroprotection in animals correlated well with hypothermia induction.
"We are greatly encouraged by this proof of concept in animals” stated Dr. Jamal Temsamani, Director of Drug Development of VECT-HORUS ”This is an important milestone in taking VH-N439 through the regulatory approval process. In light of the promising hypothermia results, we intend to demonstrate the safety and tolerability of VH-N439 during the regulatory preclinical phase and start Phase 1 clinical trials early 2016”.
Alexandre Tokay, CEO, added: “VH-N439 could be positioned as a first-in-class neuroprotective agent following sudden cardiac arrest and neonatal hypoxia/ischemia. We believe that VH-N439 could represent a better alternative to existing physical approaches and medical devices. We welcome the opportunity of new partnerships to extend this wonderful project with studies in humans”.